This article explains exon skipping, a genetic technique for treating Duchenne muscular dystrophy (DMD) by restoring the dystrophin protein using antisense oligonucleotides.
This study examines dystrophin and dystroglycan protein turnover after exon skipping therapy in DMD, highlighting protein stability changes and implications for gene correction strategies.
